The Gold Standard of Immunogenetics

Why can two siblings differ in immune compatibility? Why can the same immune-related allele help explain a population association but fail to predict an individual’s illness? The answers require understanding what genes encode, how the immune system presents molecular signals and which conclusions a laboratory result can support.

The Gold Standard of Immunogenetics begins with HLA structure and inheritance, follows molecular recognition into transplant matching and pharmacogenetics, then checks the boundaries of statistical and clinical interpretation. Precise terminology and uncertainty matter as much as the biological mechanism.

This independent educational guide includes 29 chapters, two checked fictional calculations, authentic scientific reference routes and a step-by-step evidence audit. It is not personalised medical advice or donor-selection guidance.

Chapter index

HLA mechanisms, allele naming and family inheritance · Chapters 1–10

1. Immunogenetics connects inherited variation to immune function
2. Locate the HLA system on chromosome 6
3. Class I HLA is important in CD8 T-cell recognition
4. Class II HLA supports CD4 T-cell responses
5. Follow the sequence from protein to immune recognition
6. Polymorphism changes which peptides can be presented
7. Separate genes, alleles, genotypes and haplotypes
8. Read official HLA nomenclature before interpreting labels
9. Inheritance involves one HLA-bearing chromosome from each parent
10. Worked example: sibling HLA-match probability

Typing accuracy, clinical contexts and drug responses · Chapters 11–20

11. Linkage and recombination complicate family maps
12. Typing technologies measure different amounts of information
13. Resolution and ambiguous calls must remain visible
14. Laboratory quality starts before DNA analysis
15. Genotype, expression and immune phenotype are different
16. Transplant compatibility is a clinical question, not a single score
17. Understand full, partial and haploidentical matches
18. Antibodies introduce risks beyond allele comparison
19. Distinguish graft rejection and graft-versus-host disease
20. Pharmacogenetics provides a specific, tested application

Association statistics, ethics, audits and deeper learning · Chapters 21–29

21. Autoimmune associations need causal restraint
22. Worked example: interpret a case-control odds ratio
23. Population history affects genetic frequencies and access
24. Control confounding and multiple comparisons
25. Respect consent, privacy and family implications
26. Reproducibility includes databases and analysis pipelines
27. Audit one claim from specimen to interpretation
28. Frequently asked questions about immunogenetics
29. Continue into the Gold Standard scientific ecosystem

1. Immunogenetics connects inherited variation to immune function

Immunogenetics studies how inherited genetic differences affect immune recognition, responses and disease-related outcomes. It is especially concerned with highly variable genes such as the human leukocyte antigen (HLA) system, while also including immune receptors, cytokine pathways and other inherited influences. The gold standard links a specific genetic observation to a defensible mechanism, verified laboratory evidence and an appropriately limited conclusion.

An allele name is not a diagnosis, and a statistically associated variant does not guarantee that a person will develop a disease. Genes contribute within a changing biological and environmental context. Good immunogenetics distinguishes what was measured, how confidently it was measured and what clinical or scientific decisions the evidence can legitimately support.

2. Locate the HLA system on chromosome 6

The human major histocompatibility complex, called HLA in humans, is a region on the short arm of chromosome 6 containing genes important for antigen presentation and several other immune processes. Major classical class I genes include HLA-A, HLA-B and HLA-C; major class II groups include HLA-DR, HLA-DQ and HLA-DP. These are different loci with different functions and structures.

Genetics is not a collection of interchangeable abbreviations. A result describing HLA-B cannot be read as if it describes HLA-DRB1. The NCBI Bookshelf review of MHC antigen presentation offers a foundation for understanding why HLA class I and II molecules must be distinguished.

3. Class I HLA is important in CD8 T-cell recognition

Class I HLA molecules are expressed by most nucleated cells and display peptides that commonly derive from proteins produced inside the cell. The HLA-peptide complex can be recognised by CD8 T cells, enabling immune responses to infected or altered cells under suitable conditions. HLA-A, -B and -C encode distinct classical class I molecules.

The peptides presented depend on antigen processing and the particular HLA molecule’s binding properties. A T cell does not simply read the peptide alone. Immune recognition depends on the combined molecular display and the T-cell receptor. Describing HLA as a universal ‘self’ barcode is a useful initial metaphor but misses this biological specificity.

4. Class II HLA supports CD4 T-cell responses

Class II HLA molecules commonly occur on professional antigen-presenting cells, including dendritic cells, macrophages and B lymphocytes. They display peptides often derived from proteins taken up and processed through endosomal pathways, and they interact with CD4 helper T cells. The main class II groups are DR, DQ and DP.

Class I and class II pathways have exceptions and specialised mechanisms, so avoid absolute statements such as ‘class I can never present an external antigen’. Cross-presentation provides an important exception. The basic distinction helps students build a model, but stronger scientific explanations identify its scope and where the model must be extended.

5. Follow the sequence from protein to immune recognition

A protein must be processed into peptides, transported or loaded through the relevant pathway, bound by a compatible HLA molecule, displayed at the cell surface and encountered by a suitable immune receptor. Every step can influence the response. Possessing a gene variant alone cannot show that a particular antigen was displayed or that a response happened.

Distinguish experimental levels. DNA sequence data describe alleles; protein-expression assays investigate whether a product is made; peptide-binding studies address biochemical interactions; and cell-based assays measure responses under stated conditions. Evidence from one level should not be silently promoted into certainty at the next.

6. Polymorphism changes which peptides can be presented

HLA genes are exceptionally polymorphic, meaning numerous alleles occur across human populations. Differences in peptide-binding regions can alter the range of peptides presented and the interactions with immune receptors. The resulting diversity is important for immune biology and makes donor-recipient compatibility difficult to simplify.

The IPD-IMGT/HLA Database is the specialist resource for officially named HLA sequences. Report the database release used because recognised alleles and accompanying sequence records change over time. A total number copied from an old slide should not be presented as permanently current.

7. Separate genes, alleles, genotypes and haplotypes

A locus is a position or defined genomic region; an allele is a sequence variant at a locus; a genotype describes the variant calls for the individual; a haplotype refers to variants inherited together along one chromosomal segment. A clinical report may show two alleles at each tested locus without automatically resolving which alleles travel together on a chromosome.

Use precise language. Two people may share an allele at HLA-A while differing at HLA-B, HLA-C or class II genes. The statement ‘their HLA matches’ is incomplete unless the tested loci, resolution, phase and matching definition are given.

8. Read official HLA nomenclature before interpreting labels

A name such as HLA-B*57:01 identifies a specific HLA-B allele group and protein-level sequence distinction under the official naming convention. Additional colon-separated fields can express finer distinctions, and suffixes can provide relevant expression information. The fields are not decimal numbers: HLA-B*57:01 and HLA-B*57:10 are separate allele names, not quantities.

Use IPD-IMGT/HLA and the HLA nomenclature explanation of expression suffixes for the naming system. Do not invent a suffix’s interpretation from memory when a specific clinical or experimental conclusion depends on it.

9. Inheritance involves one HLA-bearing chromosome from each parent

A child usually inherits one copy of chromosome 6 from each biological parent, carrying an HLA-region haplotype that can often be tracked through a family. Linked HLA alleles may be passed on together, though recombination can occur. Both parental contributions can be expressed; HLA is not generally a simple dominant-recessive trait.

Family diagrams should mark maternal and paternal haplotypes separately. If the diagram cannot distinguish them, a match probability may reflect a modelling assumption rather than real phased genetic data. Confirm parentage and sample identity through appropriate clinical or laboratory processes where relevant rather than treating a drawing as proof.

10. Worked example: sibling HLA-match probability

Imagine a fictional two-parent family in which the mother has distinguishable HLA-region haplotypes M1 and M2 and the father has F1 and F2. Assume each parent transmits either haplotype independently with probability one-half and ignore recombination. A child’s four possible combinations are M1F1, M1F2, M2F1 and M2F2, each with probability one-quarter.

For two full siblings, once the first child’s combination is known, the second independently has a one-half chance of receiving the same maternal haplotype and a one-half chance of the same paternal haplotype. Multiplying gives 1/2 × 1/2 = 1/4, or 25%, for matching both inherited haplotypes in this simplified model. Actual compatibility assessment is more complicated; NMDP explains the familiar 25% full-sibling match figure.

11. Linkage and recombination complicate family maps

Closely located alleles may occur together more often than expected from independent assortment. Linkage disequilibrium records this non-random association in a population; recombination during meiosis can alter transmitted combinations. Neither concept means all families share the same haplotypes or that inheritance can be predicted without uncertainty.

When modelling family matches, state whether the relevant loci are phased and whether recombination was ignored. When using population allele frequencies, avoid multiplying frequencies as though loci were independent without checking the population’s haplotype structure. Incorrect independence assumptions can produce implausibly confident predictions.

12. Typing technologies measure different amounts of information

HLA typing may involve sequence-specific probes, sequence-specific primers, targeted sequencing and other validated laboratory methods. Each has different resolution, ambiguity, quality-control and throughput characteristics. A laboratory result must identify its method and relevant limitations rather than implying that every ‘HLA test’ observes the same portions of the genome.

Sample source, consent and identification matter from collection onward. Blood and cheek swabs can be used in appropriate workflows, but the test’s purpose, accredited methods, specimen quality and confirmation requirements should be determined by the relevant laboratory and clinical team.

13. Resolution and ambiguous calls must remain visible

A report that distinguishes broad allele groups is not equivalent to one that resolves the sequence distinctions needed for a particular decision. Some typing methods leave multiple allele combinations consistent with the observed data, especially when phasing or regions outside the assay’s coverage remain unclear. The correct output may be a documented ambiguity rather than an invented precise allele.

Record the fields, version and confidence of a reported call. Before interpreting a donor match, ask whether the recipient and donor were typed at comparable resolution and whether further testing is needed. Higher resolution can resolve ambiguity, but it does not remove every biological or clinical uncertainty.

14. Laboratory quality starts before DNA analysis

A technically advanced sequencer cannot correct a mixed-up specimen label. Verify sample identity, consent, extraction controls, reference materials, coverage, contamination checks, software version and the method used to resolve uncertain calls. A reliable result includes a chain of custody and a route to investigate discrepancies.

External proficiency testing and independent quality systems can add assurance, but a certification label is not proof that every individual result was correct. Laboratories should document detection limits, reportable regions and any deviations that could affect interpretation.

15. Genotype, expression and immune phenotype are different

Having a particular HLA allele does not by itself establish how much protein is expressed in a given cell type, which peptides are displayed or how a person’s immune cells will respond. Regulatory variation, disease state, infection, treatment and cellular context may affect these downstream features. Some officially named alleles also carry expression-related suffix information.

A gold-standard interpretation describes the level of evidence: genomic sequencing, RNA expression, protein detection, functional assay or observed clinical outcome. If the evidence stops at sequence, the report should say so. This boundary prevents genetic results from turning into unsupported personal predictions.

16. Transplant compatibility is a clinical question, not a single score

HLA matching is particularly important in allogeneic blood stem cell transplantation, where donor immune cells and recipient tissues must coexist. Clinical teams consider particular HLA loci and typing resolution alongside donor availability, age, antibodies, treatment methods and other medical factors. Different transplant types and protocols may use different compatibility priorities.

The NMDP donor-selection guidance is a current primary route for understanding why a simple ‘match versus mismatch’ label cannot replace specialist donor selection. This article supplies no patient-specific donor recommendation.

17. Understand full, partial and haploidentical matches

A full match refers to agreement at the markers relevant to the specified matching framework; the framework must be named. A partial match shares some but not all evaluated markers. A haploidentical relationship typically involves sharing one parental HLA haplotype. These are not identical concepts, and the treatment plan affects how they are used.

Contemporary transplant approaches can sometimes permit donor options that earlier simplified teaching materials described as unsuitable. The existence of an alternative donor strategy does not imply equal safety for all patients. Transplant decisions require individual evaluation, donor testing and monitoring by qualified specialists.

18. Antibodies introduce risks beyond allele comparison

Recipients may have anti-HLA antibodies following exposures such as pregnancy, transfusion or transplantation. Antibodies directed against a prospective donor’s HLA can influence compatibility and outcomes in particular transplant settings. A DNA-only comparison does not reveal this immune history.

Describe what each assay measures, its reporting units, thresholds and potential false signals. Antibody evidence must be interpreted in its clinical context; a positive laboratory value should not be converted into an automatic prediction of rejection. The relevant team combines immunogenetic information with other clinical findings.

19. Distinguish graft rejection and graft-versus-host disease

Organ graft rejection often involves a recipient immune response against transplanted tissue. In blood stem cell transplantation, graft-versus-host disease involves donor-derived immune cells attacking recipient tissues. Both relate to histocompatibility, but the direction and mechanisms of immune recognition differ and should not be collapsed into one interchangeable term.

Clinical outcome depends on many additional variables, including treatment regimens and patient condition. A mechanistic explanation of HLA mismatch can improve understanding, but it is not a substitute for clinical risk prediction or the complex decisions made by transplant teams.

20. Pharmacogenetics provides a specific, tested application

Some immune-related adverse drug reactions show important associations with particular HLA alleles. A well-known example is HLA-B*57:01 and abacavir hypersensitivity. The US FDA pharmacogenetic associations table identifies HLA-B*57:01-positive patients as at increased risk and directs that abacavir not be used in that subgroup.

This example works because the allele, drug, outcome and recommended action are specified and supported by substantial evidence. It must not be generalised to every medication or every HLA association. Medication decisions require the applicable current label, a verified test and a qualified prescriber.

21. Autoimmune associations need causal restraint

Some HLA variants show statistical associations with autoimmune diseases, reflecting complex immune biology and population genetics. An association may help researchers investigate antigen presentation or risk patterns, but it usually does not mean that an allele alone causes disease or provides a definitive diagnosis.

Report what was actually compared: cases, controls, allele prevalence, adjustment variables and uncertainty. Consider linkage to nearby causal variants, population structure, environmental exposures and how participants were recruited. The association may be robust while individual-level prediction remains weak.

22. Worked example: interpret a case-control odds ratio

In a fictional study, 200 selected cases include 50 carriers of allele X and 150 non-carriers. Among 400 selected controls, 40 are carriers and 360 are non-carriers. The case-group carrier odds are 50/150 = 1/3; control carrier odds are 40/360 = 1/9. The estimated odds ratio is (1/3) ÷ (1/9) = 3.0.

This is an association within the sampled groups, not proof that the allele triples an individual’s probability of disease. Because investigators selected case and control numbers, the observed case fraction is not the disease prevalence, and the odds ratio is not automatically a population risk ratio. Check uncertainty, ancestry, study design and replication before making a causal claim.

23. Population history affects genetic frequencies and access

Allele and haplotype frequencies vary across populations partly because of ancestry, demographic history, selection and chance. These distributions matter for donor registry matching and research design. They do not justify treating people within a category as genetically identical or assigning clinical probabilities based on a broad identity label alone.

Where registration or sampling is uneven, a ‘rare’ match in one database may partly reflect who was recruited. Improving representation can improve access, while responsible reporting must avoid using genetic information to stereotype groups. A person’s actual HLA typing remains more relevant than a guessed ancestry label for individual clinical matching.

24. Control confounding and multiple comparisons

A study measuring many HLA alleles against many diseases can find apparently impressive p-values by chance. Correct for the number and dependence of comparisons, define prespecified hypotheses and seek independent replication. Linkage disequilibrium can cause neighbouring alleles to appear associated even when they are not the functional cause.

Use models that account for relevant ancestry structure and study design. Report effect sizes and uncertainty intervals rather than a naked significance threshold. Where functional experiments are possible, they can strengthen a proposed mechanism, but one functional assay does not automatically establish general clinical utility.

25. Respect consent, privacy and family implications

Immunogenetic tests may reveal information relevant not only to a participant but also to relatives. Define permitted uses, data access, sample retention, secondary research, sharing and how results can be corrected. An apparent anonymous record may be re-identifiable when combined with other genetic and demographic information.

Clinically relevant interpretations require careful communication. Avoid promising that every variant carries a definite health prediction, and do not publish identifiable genetic or family data in illustrative materials. Researchers and clinics should apply the laws, consent terms and ethical review requirements that govern their actual setting.

26. Reproducibility includes databases and analysis pipelines

Record reference genome, target regions, typing assay, software and database releases, quality thresholds, handling of ambiguous calls, exclusion rules and statistical analysis choices. A sequence call may change when a newly catalogued allele becomes available. Reanalysis should preserve the previous result and explain why an interpretation changed.

The IPD-IMGT/HLA Database provides curated official allele sequence resources, and its version reports help researchers identify precisely what was known at a given date. Reproducibility is not merely rerunning code; it means recreating the meaning of inputs and decisions.

27. Audit one claim from specimen to interpretation

Choose one claim, such as a reported HLA-B allele or a published odds ratio. Check participant or specimen identity, assay scope, read quality, allele nomenclature release, ambiguity handling, analysis population, reference method and the precise outcome being claimed. Verify calculations independently and document any uncertainty that might change the conclusion.

Then ask the harder question: what would make this claim fail under new samples, alternative reference data or another population? A gold-standard workflow actively searches for failure modes, maintains evidence for corrections and separates exploratory research from validated clinical action.

28. Frequently asked questions about immunogenetics

Is HLA the same as a blood group? No. HLA and ABO are different biological systems, and particular transplant decisions may consider both. Does an HLA match guarantee a successful transplant? No. It is one important factor among many. Are all full siblings HLA-identical? No; the classic simplified model gives a one-in-four probability.

Can one HLA allele diagnose an autoimmune condition? Usually not. Statistical associations have limited individual predictive meaning without the appropriate clinical evidence. Does more detailed typing solve every problem? No; it improves some genetic distinctions while leaving functional, clinical and sampling uncertainties. Is this guide a source of medical advice? No; it is an educational explanation.

29. Continue into the Gold Standard scientific ecosystem

Build the foundation through Genetics, Immunology, Molecular Biology and Statistics. In each, the principle is to distinguish measured evidence from interpretation and to test what transfers into a new setting.

Primary scientific and clinical reading routes: IPD-IMGT/HLA, NCBI MHC antigen-presentation review, NMDP HLA matching, NMDP donor-selection guidance and the FDA pharmacogenetics table. All fictional calculations here illustrate methods; they do not predict outcomes for any person.